Clinical Trials
40 trialsNCT06225596 2026-05-27
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2 Active not recruiting
NCT03076554 2026-05-22
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04068194 2026-05-13
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05092958 2026-05-13
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05947500 2026-05-13
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03271372 2026-05-12
ADAM
University of Washington
Phase 3 Active not recruiting
NCT03217747 2026-05-05
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05081180 2026-05-01
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
EMD Serono
Phase 1 Active not recruiting
NCT05327530 2026-04-24
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
Phase 2 Active not recruiting
NCT03971409 2026-04-17
InCITe
University of California, San Francisco
Phase 2 Active not recruiting
NCT05059522 2026-04-14
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
NCT03964532 2026-04-09
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
Phase 1/2 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT04792073 2026-04-07
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03815643 2026-03-31
Avelumab Program Rollover Study
EMD Serono
Phase 3 Active not recruiting
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03573648 2026-03-19
ImmunoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04004442 2026-03-13
COAXIN
University of Oklahoma
Phase 1 Active not recruiting
NCT03252938 2026-02-19
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Active not recruiting
NCT04848519 2026-02-19
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Phase 2 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT03944941 2026-02-05
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03744793 2026-01-09
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03391479 2025-12-18
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04266912 2025-11-25
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03147287 2025-09-30
Palbociclib After CDK and Endocrine Therapy (PACE)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05222932 2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1 Active not recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03414658 2025-07-02
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02999087 2025-05-07
REACH
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Active not recruiting
NCT03498378 2025-04-03
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 1 Active not recruiting
NCT04215146 2025-01-16
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Oncolytics Biotech
Phase 2 Active not recruiting
NCT03845166 2024-11-19
STELLAR-001
Exelixis
Phase 1 Active not recruiting
NCT03244176 2024-07-30
AvR-CHOP
Austin Health
Phase EARLY_PHASE1 Active not recruiting